Stereotaxis

(NYSEMKT) STXS

Current Price$1.55

Market Cap$151.49M

Since IPO (2004)-98%

5 Year-83%

1 Year-35%

1 Month-13%

Stereotaxis last closing stock price
Metric	Price	Date
Last close	USD 1.55	2026-07-17

Stereotaxis stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-8.82%	USD 1.70	2026-07-10
1 month	-12.92%	USD 1.78	2026-06-17
3 month	-23.65%	USD 2.03	2026-04-17
Year to date	-32.61%	USD 2.30	2025-12-31
1 year	-34.87%	USD 2.38	2025-07-17
3 year	+2.65%	USD 1.51	2023-07-18
5 year	-82.78%	USD 9.00	2021-07-16
Since inception	-97.89%	USD 73.39	2004-08-12

Stereotaxis Financials at a Glance

Market Cap

$151.49M

Revenue (TTM)

$31.20M

Net Income (TTM)

-$21.68M

EPS (TTM)

-$0.24

P/E Ratio

-6.35

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Price

$1.55

Volume

146,865

Open

$1.86

Price

$1.55

Volume

146,865

Open

$1.86

Previous Close

$1.55

Daily Range

$1.49 - $1.87

52-Week Range

$1.46 - $3.59

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Price

$1.55

Volume

146,865

Open

$1.86

Previous Close

$1.55

Daily Range

$1.49 - $1.87

52-Week Range

$1.46 - $3.59

Estimated Earnings Date

Aug 6, 2026

STXS News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Stereotaxis

Stereotaxis makes robotic systems that help doctors treat irregular heartbeats. Its technology guides flexible tools inside the heart using magnets. Hospitals use these systems to improve safety and precision during heart procedures.

Products and Services

Robotic Navigation Systems: Computer-controlled systems that guide catheters inside the heart for hospitals treating arrhythmias. These systems accounted for 31% of total revenue for the six months ended June 30, 2025.
Disposables and Accessories (34% of revenue for the six months ended June 30, 2025): Single-use tools and add-ons for heart procedures, sold to hospitals and clinics.
Other recurring revenue (35% of revenue for the six months ended June 30, 2025): Service, software, and maintenance—ongoing support, updates, and technical help for installed systems, mainly for healthcare providers.
Imaging and Information Systems: X-ray and data management tools that help doctors see and record procedures in real time.
Diagnostic and Ablation Catheters: Flexible tubes for mapping and treating heart rhythm problems, used with robotic systems.

Growth and Expansion

Acquired Access Point Technologies EP in July 2024, adding in-house catheter manufacturing.
Launched GenesisX RMN system in Europe (Q3 2024) and launched Genesis RMN system in China (Nov 2024).
Secured CE Mark for MAGiC catheter in Europe (Q1 2025) and FDA clearance for MAGiC Sweep catheter (July 2025).
Formed a strategic partnership with Osypka AG to develop new magnetic ablation catheters.
Raised $8.5M in equity in July 2025, with $4M more expected in November 2025.

What Makes Stereotaxis Stand Out

Stereotaxis operates in over 100 hospitals worldwide, supporting more than 150,000 patient procedures. Its robotic systems use magnetic fields for precise, computer-guided navigation inside the heart. The company combines capital equipment sales with recurring revenue from disposables and services.

Five Things You Need to Know

Revenue was $7M in QQ3 2025, down 18.8% from QQ3 2024.
Gross margin fell to 53% for the six months ended June 30, 2025.
Operating loss was $-7M in QQ3 2025, down 9.6% year-over-year.
Cash and cash equivalents were $7M as of June 30, 2025.

Bottom Line

Stereotaxis has expanded its product range and global reach through acquisitions and new launches. The company blends innovation in robotic navigation with a recurring revenue model, but faces ongoing profitability and cash flow challenges.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

131

CEO

David Leo Fischel, CFA, CAIA

Website

www.stereotaxis.com

Headquarters

St. Louis, MO 63101, US

STXS Financials

Key Financial Metrics (TTM)

Gross Margin

53.86%

Operating Margin

-68.49%

Net Income Margin

-69.50%

Return on Equity

-153.21%

Return on Capital

-91.53%

Return on Assets

-40.13%

Earnings Yield

-15.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$151.49M

Shares Outstanding

97.74M

Volume

146.87K

Avg. Volume

616.98K

Financials (TTM)

Gross Profit

$16.80M

Operating Income

-$21.36M

EBITDA

-$20.09M

Operating Cash Flow

-$15.35M

Capital Expenditure

-$172.00K

Free Cash Flow

-$15.52M

Cash & ST Invst.

$14.62M

Total Debt

$5.28M

Stereotaxis Performance Analysis

Stereotaxis annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 28,147,000	-19.6%
2023	2023-12-31	USD 26,771,000	-4.9%
2024	2024-12-31	USD 26,918,000	0.5%
2025	2025-12-31	USD 32,377,000	20.3%

Stereotaxis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	17.7%
Q3	2025-09-30	-15.2%
Q4	2025-12-31	15.8%
Q1	2026-03-31	-27.2%

Stereotaxis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.26	61.8%
2023	2023-12-31	USD -0.27	5.8%
2024	2024-12-31	USD -0.30	8.9%
2025	2025-12-31	USD -0.25	-15.4%

Stereotaxis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	32.6%
Q3	2025-09-30	-56.5%
Q4	2025-12-31	17.2%
Q1	2026-03-31	-2.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$6.29M

-15.8%

Gross Profit

$3.79M

-6.6%

Gross Margin

60.31%

N/A

Market Cap

$151.49M

N/A

Market Cap/Employee

$1.16M

N/A

Employees

131

N/A

Net Income

-$5.86M

-0.7%

EBITDA

-$5.47M

-0.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$14.62M

+37.9%

Total Debt

$5.28M

-10.0%

Accounts Receivable

$9.62M

+122.5%

Inventory

$10.50M

+7.0%

Long Term Debt

$4.62M

-12.5%

Short Term Debt

$662.00K

+12.6%

Return on Assets

-40.13%

N/A

Return on Invested Capital

-69.04%

N/A

Free Cash Flow

-$3.52M

-97.9%

Operating Cash Flow

-$3.44M

-93.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ARCTArcturus Therapeutics Holdings Inc.

ARCTArcturus Therapeutics Holdings Inc.$6.05-2.10%

CVRXCVRx, Inc.

CVRXCVRx, Inc.$4.91-8.91%

QTRXQuanterix Corporation

QTRXQuanterix Corporation$3.87-2.40%

HUMAHumacyte, Inc.

HUMAHumacyte, Inc.$0.66+0.77%

XGNExagen Inc.

XGNExagen Inc.$4.39+3.29%

SMTISanara MedTech Inc.

SMTISanara MedTech Inc.$25.00-1.26%

SGMTSagimet Biosciences Inc.

SGMTSagimet Biosciences Inc.$7.82+2.22%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$6.53-0.02%

NFLXNetflix

NFLXNetflix$68.95-0.07%

NOKNokia

NOKNokia$10.12-0.03%

JOBYJoby Aviation

JOBYJoby Aviation$7.23-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$17.28-0.00%

TAT&T

TAT&T$21.81-0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$67.53-0.05%

Questions About STXS

What is the current price of Stereotaxis?

Stereotaxis is trading at $1.55 per share.

What is the 52-week range for Stereotaxis?

Over the past 52 weeks, Stereotaxis has traded between $1.46 and $3.59.

How much debt does Stereotaxis have?

As of the most recent reporting period, Stereotaxis reported total debt of $5.28M.

How much cash does Stereotaxis have on hand?

Stereotaxis reported $14.62M in cash and cash equivalents in its most recent financial results.

What is Stereotaxis’s dividend yield?

Stereotaxis does not currently have a dividend yield.

Stereotaxis

Stereotaxis Financials at a Glance

STXS News

High-Tech Robotic Surgery Gets Specialized

5 of Last Week's Biggest Losers

3 Stocks Approaching Greatness

Buy or Short These Health-Care Equipment Stocks?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Stereotaxis

Products and Services

Growth and Expansion

What Makes Stereotaxis Stand Out

Five Things You Need to Know

Bottom Line

STXS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Stereotaxis Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About STXS

What is the current price of Stereotaxis?

What is the 52-week range for Stereotaxis?

How much debt does Stereotaxis have?

How much cash does Stereotaxis have on hand?

What is Stereotaxis’s dividend yield?

Premium Investing Services